ArticleCancer2026
Patterns of lung cancer incidence in adults diagnosed under age 50 in the United States, 2000-2021.
Article in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAlthough the incidence of several cancers diagnosed before age 50 years has increased, contemporary trends in early-onset lung cancer remain poorly defined, particularly across histologic and sociodemographic subgroups.
methodsA population-based cohort study was conducted via Surveillance, Epidemiology, and End Results 22 Program registries of 81,568 individuals diagnosed with lung cancer at age 20-49 years from 2000 to 2021. Age-adjusted incidence rates and annual percent change (APC) were estimated via National Cancer Institute Joinpoint regression. Overall trends were stratified by histology, sex, race/ethnicity, and state-level smoking prevalence.
resultsFrom 2000 to 2021, early-onset lung cancer incidence declined overall (average APC, -3.81%; 95% CI, -4.01% to -3.64%; p < .0001), which contrasts with rising early-onset colorectal and female breast cancers. Declines among females occurred later but were steeper for lung adenocarcinoma (LUAD; -5.14% vs. -2.82%), whereas males declined faster for non-small cell lung cancer (NSCLC) and overall. Female declines were slower relative to males in Hispanic and non-Hispanic (NH) Black individuals (2.3- and 1.08-fold difference, respectively), whereas NH White females declined 1.3-fold faster than males. Among Asian females, NSCLC incidence did not decline, and LUAD increased through 2017 (+2.45%) and remained stable in Hispanic females. In high-smoking states, male rates declined steadily (-4.32%), whereas female rates were stable until 2010, then dropped sharply, and converged with males by 2021. In low-smoking states, male rates declined 48.75% faster than female rates (-4.76% vs. -3.20%).
conclusionsEarly-onset lung cancer incidence declined overall from 2000 to 2021, except for persistent or rising LUAD among Asian and Hispanic females, which implicates emerging non-tobacco risk factors and highlights the need for targeted prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.